AI in Medicines Development: EMA Shares Progress, Risks, and Regulatory Roadmap
At the beginning of her keynote address on Artificial Intelligence (AI) in Medicines Development: Perspective From an EU Medicines Regulator, Jane Moseley, Senior Scientific Officer at the European Medicines Agency (EMA) said she would be addressing three key questions: Where do we want to get to with AI in medicines development?; Where are we now?; and How are we going to get there?
AI in Medicines Development: EMA Shares Progress, Risks, and Regulatory Roadmap Read More »











